Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma

Summary

Anemia is a common complication among cancer patients and is negatively associated with overall prognosis and therapeutic outcomes. The purpose of this study is to see if giving a dose of iron prior to any standard of care chemotherapy treatment will affect the cells that are believed to make treating melanoma harder, making melanoma more responsive to the standard of care immunotherapy.

Timeline

Start

2025-05

Primary completion

2026-06

Completion

2026-06

Drugs

Indications